Stock’s Earnings Analysis Report: Cara Therapeutics Inc (CARA), Earth Science Tech Inc (ETST), Zynerba Pharmaceuticals Inc (ZYNE)

Stock’s Earnings Analysis Report: Cara Therapeutics Inc (CARA), Earth Science Tech Inc (ETST), Zynerba Pharmaceuticals Inc (ZYNE)

Stock’s Earnings Analysis Report: Cara Therapeutics Inc (CARA), Earth Science Tech Inc (ETST), Zynerba Pharmaceuticals Inc (ZYNE)

Cara Therapeutics Inc (NASDAQ:CARA) showing dropped of -2.79% and closed at $17.42, after gaining total volume of 1.90M shares. Its earnings per share (EPS) is -$2.10 and its beta value stands at 3.16 points and has total market capitalization of $539.90 billion and a total of 31.75 million outstanding shares.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body’s peripheral nervous system. The company’s lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -17.86% and closed at $1.38, with the total traded volume of 48,674.00 shares. During last trade its minimum price was $1.31 and it gained its highest price of $1.68 and has a total of 40.91 million outstanding shares.

On March 14, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.

Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)

Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.

“I love my work, especially when it allows me to bring my passion for health and business development together, and to bring them to other people,’ says Foster-Cunningham. “This project is my new baby, and I’m excited about the prospects of helping it grow to maturity.”

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) decreased -2.81% closed at $19.75 and traded with total volume of 331,755.00 shares, while the average trading remained 364,312.00 shares. During last trade its minimum price was $19.34 and it gained the highest price of $20.36. Its market capitalization was $263.85 million.

Zynerba Pharmaceuticals Inc (ZYNE) on March 27, 2017 reported financial results for the fourth quarter and year ended December 31, 2016 and provided an overview of recent operational highlights.

“2016 was a year marked by tremendous progress for our lead development candidate, ZYN002 CBD gel, as we initiated Phase 2 trials for epilepsy, osteoarthritis and Fragile X syndrome.  I am pleased that we have completed enrollment in the epilepsy and osteoarthritis trials,” said Armando Anido, Chairman and CEO.  “We enter 2017 with great momentum and expect it to be a transformational year with several key milestones expected in the coming months, including top-line results from the three ZYN002 clinical trials and the commencement of our clinical program for ZYN001, our patent-protected pro-drug of THC in development for the treatment of fibromyalgia and peripheral neuropathic pain.”

Fourth Quarter 2016 and Recent Highlights

Completed Enrollment of Phase 2 STAR 1 Clinical Trial for ZYN002 CBD Gel in Adult Epilepsy Patients

Zynerba has completed enrollment in the Phase 2 STAR 1 randomized, double-blind, placebo-controlled clinical trial in adult patients with refractory epilepsy.  Of the 224 patients that have been screened, 170 patients have been randomized into the trial and there are 19 patients still in the eight-week baseline period.  The Company expects to meet or exceed the 180 patient target for randomization in this trial once all patients have completed the baseline period.  Patients are receiving either 195 mg or 390 mg of CBD in ZYN002 4.2% gel or placebo daily for 12 weeks.  The primary endpoint of the trial is the median reduction in seizure frequency per 28-day period compared to baseline. Top-line results are expected in July/August 2017.



Leave a reply


There are no comments on this post.

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.